Israel Decriminalizes Adult Use Cannabis in Another Step Toward Legalization -- CFN Media

Seattle, Washington, April 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing ISRACANN Biosciences Inc. [Canadian Listed: IPOT (Pending)], and how to invest in Israel’s cannabis industry.

Israel decriminalized adult use cannabis on April 1 — just days before the Jewish state’s April 9 election. The new law makes it legal for Israeli citizens to possess homegrown marijuana plants, while carrying small amounts of cannabis in public will only result in a fine rather than an arrest. The move follows similar legislation across roughly 25 other countries that have legalized cannabis to some extent — ranging from decriminalization to full recreational use.

While the country is smaller than North American cannabis markets, it has already been established as a research capital and could become a gateway to European markets. Dr. Raphael Mechoulam is widely known as the Godfather of Cannabis after discovering tetrahydrocannabinol and paving the way for medical cannabis research. Cannabis research was legal in Israel long before other countries liberalized their laws.

Israel’s unique location could also make it a key gateway to European markets. The government recently legalized cannabis exports earlier this year and analysts believe that regulations could be in place later this year. As a home to more than 740 million people, Europe is roughly double the size of the Canadian and U.S. markets, which represent the two largest legal cannabis markets in the world right now.

Investing in Israel’s Cannabis Industry

ISRACANN Biosciences Inc. [Canadian Listed: IPOT (Pending)] will be Israel’s first pure-play cannabis company to list on a Canadian exchange, with a fully-funded facility of 232,900 sq. ft. With plans to initially target the domestic market before exporting into Europe, investors may want to keep an eye on the stock as it gears up to go public in Canada under the ticker symbol IPOT later this year.

Click Here: Learn how to invest in ISRACANN Biosciences as an Accredited Investor.

With over 15 years of experience in the capital markets, President and CEO Darryl Jones took True Leaf Medicine public at a $10 million valuation and exited in 2016 with a $150 million market capitalization. He’s joined by an experienced team of cannabis and finance veterans with an established track record of success. The company will also partner with leading Israeli research institutions and universities to leverage their expertise in the market.

The company is well positioned in Israel via its agreements with three farms with cultivation licenses. These operations have a fully-funded capacity of 232,900 sq. ft. with the ability to produce 23,500 kilograms of cannabis per year. Management believes these operations can be further scaled to produce 50,000 kilograms per year with a low production cost of just 40 cents per gram given the unique climate and technologies.

What’s Next for Israel’s Cannabis Market?

It is anticipated that new guidelines will enable more patients to purchase cannabis at pharmacies with a prescription. Currently, the law is restricted to patients suffering from Parkinson’s, epilepsy, cancer, and other terminal illnesses, which has limited demand. The new law is expected to go into effect imminently.

Over the longer-term, Israel appears to be moving closer to a fully-legalized cannabis market. Mainstream political parties have been supportive of cannabis legalization and there’s widespread demand from the public for reforms. Decriminalization and wider medical cannabis use are a great first step, but the country’s cannabis market won’t realize its true potential until adult-use cannabis is legalized and export laws go into effect. Fortunately, Israel legalized exports in January 2019, initiating a massive catalyst for the Israeli market.

Click Here: Learn how to invest in ISRACANN Biosciences as an Accredited Investor.

ISRACANN Biosciences Inc. [Canadian Listed: IPOT (Pending)] plans to become fully operational in the near-term with initial harvests expected by the first quarter of 2020. Given the strong valuations across North American cannabis companies, investors may want to keep a close eye on the stock ahead of its listing on a Canadian Stock Exchange later this year. The unique exposure to Israel’s market and the potential to expand into Europe are key catalysts.

Please follow the link to read the full article on CFN:

About CFN Media

CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

Learn how to become a CFN Media client company, brand or entrepreneur:

Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand:

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone:

Disclaimer is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on (the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate., a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies.  We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. received compensation for producing and presenting high quality and sophisticated content on along with financial and corporate news.  

The above article is sponsored content. Emerging Growth LLC, which owns and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation:


Contact Data